Rifamycins--obstacles and opportunities (Q37710834)

22 August 2017

1 reference

title

Rifamycins--obstacles and opportunities (English)

1 reference

22 August 2017

Paul A Aristoff

1

1 reference

22 August 2017

George A Garcia

series ordinal

2

1 reference

22 August 2017

Paul D Kirchhoff

series ordinal

3

1 reference

22 August 2017

H D Showalter

series ordinal

4

1 reference

22 August 2017

language of work or name

1 reference

16 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

90

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

94-118

1 reference

The search for new sterilizing anti-tuberculosis drugs

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifaximin pharmacology and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifapentine for the treatment of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

New drugs for tuberculosis: current status and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifapentine: its role in the treatment of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Development potential of rifalazil and other benzoxazinorifamycins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifalazil and other benzoxazinorifamycins in the treatment of chlamydia-based persistent infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In search of new cures for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

New anti-tuberculosis drugs in clinical trials with novel mechanisms of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Managing TB in the 21st century: existing and novel drug therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Confronting the scientific obstacles to global control of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Bacterial RNA polymerase inhibitors: an organized overview of their structure, derivatives, biological activity and current clinical development status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Effect of rifamycin on protein synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifamycin-mode of action, resistance, and biosynthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

The specific inhibition of the DNA-directed RNA synthesis by rifamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Action of rifamycins on RNA polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Mechanisms of drug resistance in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Interaction of rifamycin with bacterial RNA polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Structures of RNA polymerase-antibiotic complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Structural mechanism for rifampicin inhibition of bacterial rna polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Distance-restrained docking of rifampicin and rifamycin SV to RNA polymerase using systematic FRET measurements: developing benchmarks of model quality and reliability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Is it easy to stop RNA polymerase?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifamycins do not function by allosteric modulation of binding of Mg2+ to the RNA polymerase active center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Homology modeling of wild-type, D516V, and H526L Mycobacterium tuberculosis RNA polymerase and their molecular docking study with inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

New inhibitors targeting bacterial RNA polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

A new class of small molecule RNA polymerase inhibitors with activity against rifampicin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

The RNA polymerase "switch region" is a target for inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

3-N-Substituted aminomethyl derivatives of rifamycin SV. A convenient method of synthesis, cyclization of certain derivatives, and anticellular and antiviral activities of several derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Interaction of rifamycins with mammalian nucleic acid polymerizing enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Effect of the rifamycin dimers on the activities of nucelic acid polymerases from various sources. Relation between lipophily and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Antibiotics as inhibitors of nucleic acid and protein synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Inhibition of DNA-dependent RNA polymerase reaction of Escherichia coli by an antimicrobial antibiotic, streptovaricin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Relative biological activities of individual streptovaricins and streptovaricin acetates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Electronegative groups at C-3 of rifamycin S enhance its activity toward DNA-dependent RNA polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Substituent effects on the solution conformation of rifamycin S

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Correlation of structure and activity in ansamycins: structure, conformation, and interactions of antibiotic rifamycin S

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Hydrogenation of theansa-Chain of Rifamycins. X-ray crystal structure of (16S)-16,17,18,19-tetrahydrorifamycin S

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifamycins: an insight into biological activity based on structural investigations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Conformational variety for the ansa chain of rifamycins: comparison of observed crystal structures and molecular dynamics simulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Comprehensive Study on Structure−Activity Relationships of Rifamycins: Discussion of Molecular and Crystal Structure and Spectroscopic and Thermochemical Properties of Rifamycin O

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Purification and properties of DNA-dependent RNA polymerase from Mycobacterium tuberculosis H37RV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Different rifampin sensitivities of Escherichia coli and Mycobacterium tuberculosis RNA polymerases are not explained by the difference in the beta-subunit rifampin regions I and II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

History of the Development of Rifampin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Synthesis and antibacterial activity of some derivatives of tolypomycinone. Relation between structure and activity in ansamycins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

RIFAMYCINS. XXXV. AMIDES AND HYDRAZIDES OF RIFAMYCIN B3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Synthesis and antibacterial activity of some esters, amides, and hydrazides of 3-carboxyrifamycin S. Relationship between structure and activity of ansamycins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

The influence of the carboxyl group upon the antibacterial activity of rifamycins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Oximes of 3-formylrifamycin SV. Synthesis, antibacterial activity, and other biological properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Novel rifamycins. IV. 3-Aminomethylazinomethylrifamycins, a new class of rifamycins, endowed with remarkable antibacterial activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Laboratory evaluation of a new long-acting 3-azinomethylrifamycin FCE 22250.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Unusual rearrangement of 3-hydrazino-rifamycins leading to the enlargement of the "natural" ansa bridge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Antimycobacterial activity of a new rifamycin derivative, 3-(4-cinnamylpiperazinyl iminomethyl) rifamycin SV (T9)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Antimicrobial activities of cinnamyl rifamycin derivatives, T-9 and T-11, against Mycobacterium tuberculosis and Mycobacterium avium complex (MAC) with special reference to the activities against intracellular MAC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Studies on quantitative structure-activity relationships. V. QSAR investigations of rifamycin B amides and hydrazides by utilization of the substituent entropy constant sigma s degrees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Structure-activity correlations among rifamycin B amides and hydrazides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Synthesis and biological activity of some derivatives of rifamycin P

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Activityin vitroof Rifabutin, FCE 22807, Rifapentine, and Rifampin againstMycobacterium microtiandM. tuberculosisand Their Penetration into Mouse Peritoneal Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Comparative in vitro activities of rifamycin analogues against rifampin-sensitive and rifampin-resistant Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

NMR spectroscopic analysis of new spiro-piperidylrifamycins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Synthesis and biological activity of 5'-aminobenzoxazinorifamycin derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro time-kill activities of rifalazil, alone and in combination with vancomycin, against logarithmic and stationary cultures of Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro activity of novel rifamycins against gram-positive clinical isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Acetyl migration in rifampicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Identification of urinary metabolites of rifamycin LM 427 in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

CGP 4832, a new semisynthetic rifamycin derivative highly active against some gram-negative bacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Active transport of an antibiotic rifamycin derivative by the outer-membrane protein FhuA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Highly efficient uptake of a rifamycin derivative via the FhuA-TonB-dependent uptake route in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Efficacy of benzoxazinorifamycins in a mouse model of Chlamydia pneumoniae lung infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Bactericidal efficacy of ABI-0043, a novel rifamycin, in a murine pneumococcal pneumonia model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Clinical Pharmacokinetics of Rifampicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifampin and rifabutin and their metabolism by human liver esterases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Postantibiotic effects of antituberculosis agents alone and in combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Pharmacokinetics of rifabutin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In-vitro and intracellular activity of rifabutin on drug-susceptible and multiple drug-resistant (MDR) tubercle bacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Distribution, Excretion and Toxicity of Rifazine, a New Semisynthetic Rifamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Effect of food on the pharmacokinetics of rifalazil, a novel antibacterial, in healthy male volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Isolation and identification of major metabolites of rifalazil in mouse and human

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Identification of enzymes responsible for rifalazil metabolism in human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Pharmacokinetic interactions with rifampicin : clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

A direct effect of some rifamycin derivatives on the morphology of mammalian mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro inhibition of Saccharomyces cerevisiae RNA polymerase by rifamycin derivatives (Rifamycins and yeast RNA polymerase)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Effect of metal ion catalyzed oxidation of rifamycin SV on cell viability and metabolic performance of isolated rat hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Stimulation of microsomal production of reactive oxygen intermediates by rifamycin SV: effect of ferric complexes and comparisons between NADPH and NADH

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Pharmacology and toxicology of rifamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Adverse reactions to rifampicin in antituberculosis regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Antituberculosis drugs and hepatotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Jaundice associated with rifampicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifampicin hepatitis. A clinical and histological study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Effects of long-term rifampicin administration in primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Sensitivity to rifampicin: incidence, mechanism, and prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Massive haemolysis caused by rifampicin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Failure to stimulate antibodies in man after 7 days' high-dose treatment with rifampicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Potentially Serious Side Effects of High-dose Twice-weekly Rifampicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Immediate hypersensitivity to rifampicin in 3 patients: diagnostic procedures and induction of clinical tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Antimicrobial Agents Induce Monocytes to Release IL-1α, IL-6, and Tnf and Induce Lymphocytes to Release IL-4 and TNFτ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifampin augments cytokine-induced nitric oxide production in human alveolar epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifampin levels, interferon-gamma release and outcome in complicated pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Novel agents in the management of Mycobacterium tuberculosis disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Cross-resistance of Escherichia coli RNA polymerases conferring rifampin resistance to different antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Identification and preparation of damavaricins, biologically active precursors of streptovaricins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

Ansamycins. Chemistry, biosynthesis and biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

The inhibition of bacterial RNA synthesis by the rifamycin antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

ADP-ribosylation as an intermediate step in inactivation of rifampin by a mycobacterial gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

A new tolypomycin-Y derivative: in vitro and in vivo antimicrobial activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

New rifamycins modified at positions 3 and 4. Synthesis, structure and biological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

Novel rifamycins. III. Synthesis and antibacterial activity of 3-amidino- and of 4-aminoimidazolo[4,5-c]rifamycin derivatives

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

Biological activity of a new class of rifamycins Spiro-piperidyl-rifamycins

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

Adverse Effects of Rifampin

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

Relationship between rifampicin-dependent antibody scores, serum rifampicin concentrations and symptoms in patients with adverse reactions to intermittent rifampicin treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.02.001

7 January 2021

10.1016/J.TUBE.2010.02.001

Identifiers

DOI

1 reference

22 August 2017

1 reference